CHI3L1 and breast carcinoma: For verification of the mammary tumor disease progression either with or without additional macrophages, two immune-related proteins CHI3L1 and LCN2, which both have been identified as prognostic biomarkers in breast cancer patients [12–14], were incorporated in the current study.